共 16 条
[1]
Intratumor Heterogeneity: Evolution through Space and Time. Charles Swanton. Cancer Research . 2012
[2]
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Linda Sofie Lindstrom,Eva Karlsson,Ulla M. Wilking. Journal of Clinical Oncology . 2012
[3]
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. Gerlinger Marco,Rowan Andrew J,Horswell Stuart,Larkin James,Endesfelder David,Gronroos Eva,Martinez Pierre,Matthews Nicholas,Stewart Aengus,Tarpey Patrick,Varela Ignacio,Phillimore Benjamin,Begum Sharmin,McDonald Neil Q,Butler Adam,Jones Da. The New England Quarterly . 2012
[5]
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet,The . 2005
[8]
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update[J] . Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,Donald C. Allred,John M.S. Bartlett,Michael Bilous,Patrick Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance
[9]
International Agency for Research on Cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=breast . 2012